MedTrace Logo

Safety, Efficacy, and Tolerability Study of PF-06480605 in Subjects With Moderate to Severe Ulcerative Colitis.

NCT02840721 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2023-10-23

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety, tolerability, and efficacy of PF-06480605 in subjects with moderate to severe ulcerative colitis.

Conditions

  • Colitis, Ulcerative

Interventions

DRUG

PF-06480605

PF-06480605 500 mg IV Q2W x 7 Doses

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Telavant, Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-26
Primary Completion
2018-05-31
Completion
2018-08-30
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Italy
  • Netherlands
  • Poland
  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02840721 on ClinicalTrials.gov